

1  
2 **Therapeutic efficacy of Honey and *Nigella sativa* against COVID-19:**  
3 **A multi-center randomized controlled clinical trial**  
4 **(HNS-COVID-PK)**

5  
6 Sohaib Ashraf<sup>\*#1</sup>, Shoaib Ashraf<sup>\*#2</sup>, Moneeb Ashraf<sup>#3</sup>, Muhammad Ahmad Imran<sup>#4,5</sup>,  
7 Larab Kalsoom<sup>db5, 6</sup>, Uzma Nasim Siddiqui<sup>db7</sup>, Muhammad Ghufuran<sup>db8</sup>, Nighat Majeed<sup>6</sup>,  
8 Iqra Farooq<sup>9,10</sup>, Zaighum Habib<sup>11</sup>, Abubakar Hilal<sup>1</sup>, Zain-ul-Abdin<sup>1,12</sup>, Ayesha Khaqan<sup>1</sup>,  
9 Muhammad Kiwan Akram<sup>13</sup>, Sidra Ashraf<sup>14</sup>, Rutaba Akmal<sup>15</sup>, Sundas Rafique<sup>5,16</sup>,  
10 Khawar Nawaz<sup>17</sup>, Shahroze Arshad<sup>12,18</sup>, Suhail Ahmad<sup>19</sup>, Kanwal Hayat<sup>1</sup>, Ali Arshad<sup>5, 11, 20</sup>,  
11 Muhammad Faisal Nadeem<sup>21</sup>, Muhammad Hassan<sup>22</sup>, Abeer-bin-Awais<sup>23</sup>, Muhammad Azam<sup>24</sup>,  
12 Muhammad Suhail<sup>26</sup>, Sibgha Zulfiqar<sup>27</sup>, Imran Anwar<sup>28</sup>, Saulat Sarfraz<sup>23</sup>, Ayesha Hamayoun<sup>29</sup>,  
13 Amber Malik<sup>30</sup>, Hui Zheng<sup>31,32</sup>, Talha Mahmood<sup>33</sup>, Mahmood Ayyaz<sup>10,34</sup>, Ali Ahmad<sup>\*35</sup>,  
14 Muhammad Ashraf<sup>\*36</sup>, Qazi Abdul Saboor<sup>\*1</sup>, Mateen Izhar<sup>\*4</sup>

15  
16 Corresponding email address: [sohaib-ashraf@outlook.com](mailto:sohaib-ashraf@outlook.com)

17 \* Corresponding authors

18 # Joint First Author

19 db Joint Second Author

20  
21 **Affiliations:**

- 22 1. Department of Cardiology, Shaikh Zayed Post-Graduate Medical Institute, Lahore,  
23 Pakistan.
- 24 2. Department of Pathobiology, Riphah College of Veterinary Sciences, Riphah University,  
25 Lahore, Pakistan.
- 26 3. Department of Pharmacology, King Edward Medical University, Mayo Hospital, Lahore,  
27 Pakistan.
- 28 4. Department of Microbiology, Shaikh Zayed Post-Graduate Medical Institute, Lahore,  
29 Pakistan.
- 30 5. Division of Telemedicine, Doctor's Lounge, Lahore, Pakistan.
- 31 6. Department of Internal Medicine, Services Institute of Medical Sciences, Lahore,  
32 Pakistan.
- 33 7. Department of Internal Medicine, Shaikh Zayed Post-Graduate Medical Institute, Lahore,  
34 Pakistan.
- 35 8. Medico Cirujano, ESACHS (Empresa de Servicio Externo de la Asociacion Chilena de  
36 Seguridad), Chile.
- 37 9. Department of Pediatrics surgery, Children Hospital, Lahore, Pakistan.
- 38 10. Department of Surgery, Services Institute of Medical Sciences, Lahore, Pakistan.
- 39 11. Department of Orthopedics, Tehsil Head Quarter, Ferozwala, Shaikhupura, Pakistan
- 40 12. Division of General Medicine, Ali Clinic, Lahore, Pakistan.
- 41 13. Department of Nutrition, University of Veterinary and Animal Sciences, Lahore,  
42 Pakistan.
- 43 14. Department of Biochemistry, College of Veterinary Sciences, Jhung, Pakistan.
- 44 15. Department of Community Medicine, Sahara Medical College, Narowal, Pakistan.
- 45 16. Department of Internal Medicine, Mayo Hospital, Lahore, Pakistan.

- 46 17. Department of Pediatrics, Sunny Downstate/Kings Country Medical Center, New York,  
47 USA.
- 48 18. Department of Pediatrics Oncology, Shaukat Khanum Hospital, Lahore, Pakistan,
- 49 19. Department of Poultry Production, University of Veterinary and Animal Sciences,  
50 Lahore, Pakistan.
- 51 20. Department of Cardiology, Punjab Institute of Cardiology, Lahore, Pakistan.
- 52 21. Institute of Pharmaceutical Sciences, University of Veterinary and Animal Sciences,  
53 Lahore, Pakistan.
- 54 22. Department of Cardiothoracic Surgery, Shaikh Zayed Post-Graduate Medical Institute,  
55 Lahore, Pakistan.
- 56 23. Department of Radiology, Shaikh Zayed Post-Graduate Medical Institute, Lahore,  
57 Pakistan.
- 58 24. Department of Statistics, University of Veterinary and Animal Sciences, Lahore,  
59 Pakistan.
- 60 25. Department of Medicine, Massachusetts General Hospital, Harvard Medical School,  
61 Boston, MA, USA.
- 62 26. Department of Anatomy, Shaikh Khalifa Bin Zayed Al-Nahyan Medical and Dental  
63 College, Lahore, Pakistan
- 64 27. Department of Physiology, Shaikh Khalifa Bin Zayed Al-Nahyan Medical and Dental  
65 College, Lahore, Pakistan
- 66 28. Department of General Surgery, Shaikh Zayed Post-Graduate Medical Institute, Lahore,  
67 Pakistan.
- 68 29. Department of Community Medicine, Shaikh Khalifa Bin Zayed Al-Nahyan Medical and  
69 Dental College, Lahore, Pakistan
- 70 30. Department of Cardiology, Evercare Hospital, Lahore, Pakistan.
- 71 31. Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
- 72 32. Biostatistics Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
- 73 33. Department of Pulmonology, Shaikh Zayed Post-Graduate Medical Institute, Lahore,  
74 Pakistan.
- 75 34. Division of General Surgery, National Hospital and Medical Center, Lahore, Pakistan
- 76 35. Centre Hospitalier Universitaire (CHU) Sainte Justin/University of Montreal, Montreal,  
77 Qc, Canada.
- 78 36. Department of Pharmacology and Toxicology, University of Veterinary and Animal  
79 Sciences, Lahore, Pakistan.
- 80

## 81 **BACKGROUND**

82 Coronavirus Disease 2019 (COVID-19) is causing havoc across the globe. Since no effective  
83 treatment exists for the disease, there is a dire need to find one. Honey and *Nigella sativa* (HNS)  
84 are two natural food ingredients with anti-inflammatory, anti-viral, anti-microbial and immune  
85 modulating properties. We investigated whether they could be beneficial in COVID-19 patients.

## 86 **METHODS**

87 We conducted an add-on, randomized, open label, placebo-controlled clinical trial using parallel  
88 group design. This was a multi-center study with superiority framework conducted in RT-PCR  
89 confirmed COVID-19 adults showing moderate or severe disease. A study period of three months  
90 was defined. Patients presenting with multi-organ failure, ventilator support and chronic diseases  
91 (except diabetes mellitus and hypertension) were excluded. All patients receiving standard care  
92 were randomized into treatment and control groups. In the treatment group, patients received HNS  
93 in predefined doses for up to 13 days. Outcome measures (time taken for alleviation of symptoms,  
94 viral clearance, clinical status improvement and mortality etc) were assessed along the course of  
95 the trial.

## 96 **RESULTS**

97 Of 1046 patients testing positive for the SARS-CoV-2, 210 with moderate and 103 with severe  
98 disease were randomized into treatment and control groups. For the moderate cases, 107 were  
99 assigned to the HNS group and 103 to the control group, whereas for the severe cases, 50 were  
100 assigned to the HNS group and 53 to the control group. In both the moderate and severe cases,  
101 HNS treatment was associated with an earlier alleviation of disease symptoms, by 3 and 7 days  
102 (HR: 6.11; 95% CI: 4.23-8.84,  $P < 0.0001$  and HR: 4.04; 95% CI, 2.46-6.64,  $P < 0.0001$ )  
103 respectively. The treatment was also associated with significant earlier viral clearance in both the  
104 moderate and severe disease groups (4 days earlier reduction in median viral clearance time  
105 (moderate HR: 5.53; 95% CI: 3.76-8.14,  $P < 0.0001$  and severe HR: 4.32; 95% CI: 2.62-7.13,  
106  $P < 0.0001$ ).). Also, a higher %age of patients cleared virus in the HNS group. Moreover, in the  
107 intention-to-treat analysis, the HNS groups led to a lower (better) clinical score on day 6 with  
108 resumption of normal activity among 63.6% of the moderate (OR: 0.07; 95% CI: 0.03-0.13,  
109  $P < 0.0001$ ) and 28% of severe cases (OR: 0.03; 95% CI: 0.01-0.09,  $P < 0.0001$ ). Furthermore, a  
110 significant reduction in mortality among severe patients was observed in the HNS arm (4% versus  
111 18.87%, OR: 0.18; 95% CI: 0.02-0.92,  $P = 0.029$ ). No HNS-related adverse effects were noted.

112 **CONCLUSIONS**

113 The HNS treatment resulted in a significant reduction in in the severity of clinical symptoms,  
114 earlier viral clearance and reduced mortality in COVID-19 patients. In the current study, it  
115 represents a safe, effective, over the counter and affordable therapy for this disease and could  
116 potentially lower burden on health care systems across the World. It can be used alone or in  
117 combination with other treatments to achieve potentiating effects. (Funded by Smile Welfare  
118 Organization, Shaikh Zayed Medical Complex and Services Institute of Medical Sciences; NIH  
119 Clinical Trial Register number: **NCT04347382**.)

120

121 **KEY WORDS**

122 COVID-19, SARS-CoV-2, Honey, Nigella sativa, Randomized Controlled Trial

## 123 **BACKGROUND:**

124 The COVID-19 pandemic, caused by the novel coronavirus named SARS-CoV-2, has infected  
125 more than forty million people and has resulted in more than a million deaths in the world<sup>(1)</sup>. In  
126 the absence of an effective prophylactic vaccine, there is an urgent need for finding effective  
127 treatments for COVID-19 patients. At a minimum, an ideal treatment should expedite recovery  
128 from the disease, decrease viral transmission in the community by earlier viral clearance from the  
129 infected patients and reduce mortality. In this context, certain treatments including  
130 hydroxychloroquine/azithromycin, lopinavir-ritonavir, remdesivir, dexamethasone, convalescent  
131 plasma and antibody therapies have shown some efficacy<sup>(2-8)</sup>. However, there is still a long way to  
132 go before we have an effective treatment regimen for severe COVID-19 patients. Towards this  
133 end, we have conducted a clinical trial in which we have investigated the potential efficacy of a  
134 combination of honey and *Nigella sativa* (HNS) in treating COVID-19 patients.

135  
136 Both components of HNS have anti-viral, anti-microbial, anti-inflammatory and immune  
137 stimulating effects with proven safety profiles<sup>(9-13)</sup>. Beneficial effects of honey against different  
138 viruses including rubella virus, Herpes Simplex virus, Hepatitis virus, and Varicella Zoster virus  
139 have been reported earlier<sup>(14, 15)</sup>. Moreover, in silico molecular docking studies have shown that  
140 six flavonoid compounds from honey might inhibit SARS-CoV-2 replication by binding to the  
141 viral 3-chymotrypsin-like-cysteine protease<sup>(16)</sup>. Honey has also shown efficacy against several  
142 multidrug resistant bacteria, especially in synergism with antibiotics<sup>(17, 18)</sup>. Honey also exhibits  
143 immunity-boosting effects mainly via its polyphenolic components, which stimulate both innate  
144 and adaptive immune responses<sup>(19)</sup>. Its use has been shown to be beneficial in upper respiratory  
145 tract infections<sup>(20)</sup>.

146  
147 *Nigella sativa* (NS), a widely used medicinal plant of the family Ranunculaceae and commonly  
148 known as Black Cumin or Kalonji, has been shown to exert antiviral effects against a variety of  
149 viruses such as Mouse Cytomegalovirus and HCV<sup>(21-23)</sup>. It has also been shown to decrease  
150 replication of SARS-CoV in vitro in cell cultures<sup>(24)</sup>. Moreover, molecular docking studies have  
151 shown that some of its components such as nigelledine,  $\alpha$ -hederin and thymoquinone, etc., have  
152 high affinity with several SARS-CoV-2 enzymes and proteins. In fact, they exhibit an energy  
153 complex score better than that of chloroquine, hydroxychloroquine and favipiravir, the drugs that

154 have shown some anti-SARS-CoV-2 effects<sup>(25)</sup>. The components' antimicrobial properties against  
155 various microbes as well as their anti-inflammatory and immunomodulatory effects have also been  
156 established<sup>(13, 26, 27)</sup>.

157  
158 As honey and *Nigella sativa* show similar pharmacological profiles, we reasoned that the  
159 combination could be more effective in attenuating severity of the disease, controlling viral  
160 replication and curing COVID-19 patients. In fact the combination has been used successfully in  
161 a variety of disease conditions<sup>(28-32)</sup>. We report here that the HNS treatment results in earlier  
162 recovery and viral clearance in COVID-19 patients.

## 163 **METHODOLOGY:**

### 164 **PATIENTS**

165 2523 suspected COVID-19 presenting within three months of study duration in four health care  
166 facilities were tested for SARS-CoV-2 by RT-PCR of their nasopharyngeal swabs in International  
167 Organization for Standardization (ISO) certified designated laboratories of Pakistan. The test  
168 positive, adult males and non-pregnant females, who presented to seek medical care within 96 h  
169 of ailment underwent randomization. Exclusion criteria included having no or mild clinical  
170 symptoms, inability to give written consent, multi-organ dysfunction, ventilator support, septic  
171 shock, known hypersensitivity to HNS and chronic illness other than hypertension and diabetes  
172 mellitus.

### 173 **TRIAL DESIGN AND OVERSIGHT**

174 This was an investigator-initiated, open-label-placebo and randomized controlled trial conducted  
175 from April 30 to July 29, 2020 in four medical care facilities in Pakistan (Shaikh Zayed Medical  
176 Complex, Services Institute of Medical Sciences, Doctor's Lounge and Ali Clinic; all located in  
177 Lahore). Written informed consent was obtained from each participant. Eligible patients were  
178 stratified based upon the severity of their clinical symptoms into two groups: mild to moderate  
179 (cough, fever, sore throat, nasal congestion, malaise and/or shortness of breath), and severe cases  
180 (fever and/or cough along with pneumonia, severe dyspnea, respiratory distress, tachypnea (>30  
181 breaths/min) or hypoxia (SpO<sub>2</sub> <90% on room air)<sup>(33)</sup>. The severity of the disease was defined as  
182 outlined in the Clinical Management Guidelines for COVID-19 by the Ministry of National Health  
183 Services, Pakistan. Within each of these two groups, patients were randomized (by lottery) into  
184 treatment and control groups. The HNS group received honey (1 mg) plus *Nigella sativa* seeds (80

185 mg) per kg body weight orally in 2-3 divided doses daily for up-to 13 days while the control group  
186 received placebo (empty capsules). Additionally, each patient in the trial received standard care  
187 therapy (SCT) as advised by the treating physician, following the clinical management guidelines  
188 for COVID-19 established by the Ministry of National Health Services of Pakistan. SCT primarily  
189 comprised of anti-pyretic drugs, antibiotics, supplemental oxygen and mechanical ventilation.  
190 The trial was approved by the institutional review boards of Shaikh Zayed Medical Complex and  
191 Services Institute of Medical Sciences. It was supervised by an independent trial steering  
192 committee. The trial's executive committee vouched for accuracy, anonymity of the data and for  
193 compliance (Supplementary Appendix 1). The trial was conducted as an urgent study during peak  
194 of the COVID-19 outbreak in Pakistan (May-July 2020), and in accordance with principles of  
195 Good Clinical Practice Guidelines of the International Conference on Harmonization.

## 196 **CLINICAL AND LABORATORY MONITORING**

197 The study participants were assessed for clinical symptoms daily by an on-site investigator  
198 (nurse/doctor) for 13 days. During the study, when a patient recovered and remained asymptomatic  
199 for 48 h, he/she underwent a second SARS-CoV-2 RT-PCR test within the next 48 h (Figure 1). If  
200 the patient tested negative, he/she was deemed to have cleared the infection and his/her treatment  
201 was stopped. In case of a positive test, a third PCR test was performed on day 14 with no further  
202 follow-up. A clinical grading score (CGS) was recorded for each patient on day 0, 4, 6, 8, 10 and  
203 12. It was based on a seven-point ordinal scale: grade 1 (not hospitalized, no evidence of infection  
204 and resumption of normal activities), grade 2 (not hospitalized, but unable to resume normal  
205 activities), grade 3 (hospitalized, not requiring supplemental oxygen), grade 4 (hospitalized,  
206 requiring supplemental oxygen), grade 5 (hospitalized, requiring nasal high-flow oxygen therapy  
207 and/or noninvasive mechanical ventilation), grade 6 (hospitalized, requiring ECMO and/or  
208 invasive mechanical ventilation) and grade 7 (death). This scale has previously been used as end  
209 point in clinical trials in COVID-19 patients<sup>(3, 4)</sup>. Body temperature was measured, and fever was  
210 graded as no fever (0; 98-99 °F), mild (1; >99-<100 °F), moderate (2; 100-101.9 °F) and severe  
211 (3; ≤102°F). Serum C-reactive Protein (CRP) levels were measured by ELISA kit (Invitrogen,  
212 USA).

213 Safety outcomes including adverse events were categorized according to the National Cancer  
214 Institute Common Terminology Criteria for Adverse Events, version 4.0. Laboratory  
215 investigations were assessed as a part of the protocol as per recommendations of the treating

216 physician. Trial safety was monitored by the trial steering committee. For the patients who were  
217 discharged before day 13 or were home-quarantined, the follow-up was done by telemedicine.

## 218 **OUTCOME MEASURES**

219 The primary outcomes were viral clearance (negative RT-PCR for the SARS-CoV-2 RNA),  
220 alleviation of clinical symptoms and the lowering of CGS on day 6. Secondary outcomes included  
221 reduction in fever degree (day 4), CRP levels (day 6), severity of symptoms (day 8), CGS score  
222 (day 10) and mortality on day 30.

## 223 **STATISTICAL ANALYSIS**

224 In univariate analyses, we used a log-rank test to compare time taken for viral clearance, alleviation  
225 of symptoms, time to improvement in severity of clinical symptoms, degree of fever, cough,  
226 shortness of breath, myalgia and how sick do you feel. Kaplan Meier method was applied to  
227 estimate survival curves for time for alleviation of symptoms and viral clearance. The Fisher's  
228 Exact test was used to compare 30-day mortality. In multivariate analyses, we used a multivariate  
229 regression models to adjust for the effects of age (<40 or >=40), gender, baseline clinical status  
230 grade, history of diabetes/hypertension and oxygen use. In the multivariate analyses of ordinal  
231 outcomes, we used ordinal logistic regression models assuming proportional odds. We also used a  
232 linear regression model to analyze the continuous outcome CRP and Cox proportional hazards  
233 models to analyze time to symptom alleviation and the time to viral clearance. SAS version 9.4  
234 (SAS Institute Inc., Cary, NC) was used for these analyses.

235

## 236 **RESULTS:**

### 237 **DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF THE PATIENTS**

238 Initial COVID-19 screening was done on 2523 patients of which 1046 patients tested positive for  
239 the SARS-CoV-2 nucleic acid. From these patients, 313 met the inclusion criteria (Figure 1). Based  
240 upon the spectrum of their clinical symptoms, they were stratified into two groups: moderate and  
241 severe. The two groups comprised 210 and 103 patients, respectively. The patients within each of  
242 the two groups were randomly assigned to the treatment and control groups. The number of  
243 patients in moderate control, moderate HNS, severe control and severe HNS were 103, 107, 53  
244 and 50, respectively. Their baseline demographics with clinical and laboratory parameters are

245 shown in Table 1. Paracetamol and azithromycin were the top two prescribed drugs as part of the  
246 SCT. Two patients opted for home quarantine despite needing oxygen therapy.

### 247 **PRIMARY OUTCOMES**

248 Primary outcomes are shown in **Table 2**. Alleviation of COVID-19 symptoms for patients in the  
249 HNS groups occurred earlier than control groups: 4 versus 7 days for the moderate patients (HR:  
250 6.11; 95% CI: 4.23-8.84;  $P < 0.0001$ ) and 6 versus 13 days for the severe disease patients (HR: 4.04;  
251 95% CI: 1.53-3.58;  $P < 0.0001$ ). Viral clearance (being negative for the SARS-CoV-2 RT-PCR test)  
252 occurred 4 days sooner in the HNS group for both moderate (HR: 5.53; 95% CI: 3.76-8.14;  
253  $P < 0.0001$ ) and severe cases (HR: 4.32; 95% CI: 2.62-7.13;  $P < 0.0001$ ). The Kaplan-Meier curves  
254 for these variables are shown in Figure 2. In moderate patients, the HNS group resumed while  
255 control group was unable to resume activities of daily life as evident by the lower median CGS at  
256 day 6 (odds ratio: 0.07; 95% CI: 0.03-0.13;  $P < 0.0001$ ). Meanwhile, in severe groups, the HNS  
257 cases were discharged whereas the control cases were hospitalized on supplemental oxygen as per  
258 median CGS at day 6 (Odds Ratio: 0.03; 95% CI: 0.01-0.09;  $P < 0.0001$ ).

### 259 **SECONDARY OUTCOMES**

260 There were significant differences in all secondary outcomes between the treatment and control  
261 groups (see **Table 2 for secondary outcomes**). In moderate COVID-19 patients, degree of fever  
262 (median) was 100-101.9°F (moderate) in the control group while HNS arm participants were  
263 afebrile on day 4 (OR: 0.05; 95% CI: 0.03-0.1;  $P < 0.0001$ ). A significant reduction in degree of  
264 fever was observed in the severe cases on day 4 (OR: 0.21; 95% CI: 0.09-0.46;  $P = 0.0001$ ). CRP  
265 levels decreased significantly ( $P < 0.0001$ ) on day 6 in both the HNS groups compared with their  
266 respective control groups. As per median degree of symptom severity on day 8, 98.13% patients  
267 were asymptomatic in HNS treated moderate cases in comparison to 56.31% in the control group  
268 (OR: 0.009; 95% CI: 0.001-0.08;  $P < 0.0001$ ). In severe cases, more patients were asymptomatic in  
269 the HNS group while more had moderate symptoms (median) in the control arm (OR: 0.1; 95%  
270 CI: 0.04-0.24). By day 10, 96.26% of the moderate cases patients fully resumed normal activities  
271 with HNS compared to 68.93% in control group (OR: 0.07; 95% CI: 0.02-0.21). For the severe  
272 group, the median CGS at day 10 revealed that HNS cases resumed normal activities while control  
273 patients were still hospitalized requiring oxygen therapy (OR: 0.05; 95% CI: 0.02-0.15). The  
274 distribution of patients in the ordinal-scale categories over time is shown in Figure 3. Thirty-day  
275 morality was 18.87% in control group and 4% with HNS therapy (OR: 0.18 95% CI: 0.02-0.92).

## 276 **ADDITIONAL OUTCOMES**

277 In HNS group, median day achievement of normal status on ordinal scale was earlier in severity  
278 of symptoms (moderate, 5 versus 8, HR; 4.49 (3.15-6.38),  $P<0.0001$  and severe, 7 versus 13 HR;  
279 2.74 (1.68-4.49) ,  $P<0.0001$ ), degree of fever [4 versus 8, HR; 4.17 (2.98-5.84),  $P<0.0001$  and  
280 severe 6 versus 10, HR; 2.64 (1.74-4.11),  $P<0.0001$ ), degree of cough [moderate 5 versus 7, HR;  
281 2.67 (1.73-4.12),  $P<0.0001$  and severe 6 versus 9, HR; 2.04 (1.26-3.31),  $P=0.0001$ ], degree of  
282 shortness of breath (severe 6 versus 13 HR; 2.39 (1.48-3.87),  $P<0.0001$ ), degree of myalgia  
283 (moderate 4 versus 6 HR; 3.34 (2.14-5.25),  $P<0.0001$ ) severe 5 versus 9, HR; 2.75 (1.62-4.69),  
284  $P<0.0001$ ) and how sick do you feel (moderate 5 versus 8 HR (3.55 (2.55-4.93),  $P<0.0001$  and  
285 severe 7 versus 13 HR; 2.87 (1.75-4.69),  $P<0.0001$ ) (Table 2). Distribution on degree of fever,  
286 cough, myalgia, feeling of sickness, emotional status, shortness of breath, oxygen saturation,  
287 oxygen requirement and severity of symptoms over 13 days is given in supplementary Tables S2-  
288 S10. No evident adverse effects were noted with HNS.

289

## 290 **DISCUSSION**

291 The study was a multicenter open-label, randomized, placebo-controlled clinical trial investigating  
292 the therapeutic efficacy of HNS against COVID-19. To the best of our knowledge, this trial is the  
293 first of its kind in which a combination of two natural substances was investigated. Current study  
294 showed superior efficacy of HNS for COVID-19 in all studied outcomes. About half of the patients  
295 in the control groups required double time to become asymptomatic compared with those in the  
296 HNS group (Figure 2). In severe cases, HNS group had a significantly lower recovery time  
297 compared with the control group (6 days versus 13 days,  $P<0.0001$ ). In comparison to this, the  
298 recovery time reported for remdesivir was 10 days versus 15 days for the control ( $P<0.001$ )<sup>(5)</sup>  
299 whereas lopinavir-ritonavir resulted in no decrease in the recovery time (16 days versus 16 days;  
300  $P=0.09$ )<sup>(3)</sup>. In our study, in ~50% of cases, SARS-CoV-2 RT-PCR became negative 4 days sooner  
301 in HNS than in control groups. Mortality among severe cases in comparison to control group was  
302 27.0% (versus 25.0%) for hydroxychloroquine<sup>(2)</sup>, 19.2% (versus 25.0%) for lopinavir-ritonavir<sup>(3)</sup>,  
303 15.7% (versus 24.0%) for convalescent plasma<sup>(34)</sup>, 11.4% (versus 15.2%) for remdesivir<sup>(5)</sup>, 22.9%  
304 (versus 25.7%) for dexamethasone<sup>(8)</sup> and only 4% (versus 18.87%) for HNS. Thus, HNS provided  
305 clinical superiority in reducing mortality in COVID-19 patients. Of note, combined mortality data  
306 provided by Solidarity and ACTT-1 for remdesivir and by Solidarity and Recovery trial for

307 lopinavir-ritonavir failed to provide statistical improvement in mortality<sup>(35)</sup>. In contrast to these  
308 drugs, HNS represents a safer and more affordable option that can be used as an in-house remedy.

309  
310 The trial results show that the use of HNS in COVID-19 patients promotes viral clearance and  
311 reduces severity of the disease. The beneficial effects of the treatment are particularly encouraging  
312 as our inclusion criteria were very stringent: excluding asymptomatic patients as well as patients  
313 with mild symptoms. The trial results are in line with anti-viral, anti-microbial, anti-inflammatory  
314 and immune stimulating effects of honey and *Nigella sativa*<sup>(9-13)</sup>. Anti-diabetic, anti-hypertensive,  
315 cardio-protective and broncho-dilatory properties of HNS make it even more beneficial in diabetic,  
316 hypertensive, cardiac and asthmatic patients which have a higher COVID-19 associated mortality  
317 <sup>(36, 37)</sup>. Furthermore, anti-platelet and anti-coagulant effects of HNS also shield COVID-19 patients  
318 from thromboembolic complications, which are main cause of morbidity and death in this  
319 disease<sup>(38)</sup>. Hepato- and reno-protective nature of HNS gives added advantage over other drugs in  
320 limiting COVID-19 related hepatic and renal injuries<sup>(36, 37)</sup>. Anti-pyretic, analgesic and antitussive  
321 properties of HNS also provide symptomatic relief<sup>(39, 40)</sup>. Furthermore, HNS's antimicrobial  
322 properties and synergism with other antibiotics against superadded infections prevent sepsis  
323 related deaths <sup>(17, 18)</sup>. These findings strengthen the use of HNS as a potential candidate for  
324 combating SARS-CoV-2 worldwide.

325  
326 Our study has some limitations including the fact that it was an open label study. Honey and NS  
327 were not administered as individual treatments to the patients. Hence, the effects of each of the  
328 two components of HNS (i.e., honey and NS) as well as their additive or synergistic effects, if any,  
329 remain unknown. Patients on ventilator support were not enrolled in this study. Also, we cannot  
330 exclude any favorable psychological effect of HNS on its users due to their religious beliefs. A  
331 multinational study with larger sample size is required to investigate potential variations in  
332 responses to the treatment in COVID-19 patients from different racial and ethnic origins.

333

## 334 **CONCLUSIONS**

335 HNS is a safe and effective therapy for COVID-19 patients and promotes viral clearance, quicker  
336 recovery and survival. Its affordability (< \$5 for the whole treatment course), over the counter  
337 availability and ease of administration (as an easily practicable home-based remedy) will make

338 this treatment very attractive. Furthermore, as an inexpensive nutraceutical, HNS could be used  
339 alone or in combination with other drugs for additive effects. The treatment is very likely to reduce  
340 burden on health care systems in a significant manner.

341


#### 342 **ACKNOWLEDGEMENTS:**

343 Firstly, the authors would like to pay gratitude to all the patients who participated in this research.  
344 Special thanks to the Government of Pakistan and Smile Welfare Organization for providing free  
345 COVID-19 testing facilities and honey and *Nigella sativa*. All the clinicians, paramedical and  
346 laboratory staff who assisted the conduction of this study are worth appreciating. The team would  
347 like to acknowledge Zaheer Ahmad, PhD, (Professor of Botany, Government University Lahore,  
348 Pakistan) for testing the purity of honey and *Nigella sativa* used in the trial.

349

#### 350 **AUTHORS' CONTRIBUTIONS:**

351 SA, ShA, MoA and MAI contributed equally to this paper and share joint first authorship. SA,  
352 ShA, AA, MA, QAS and MI share joint corresponding authorship. LK, UNS, and MG were co-  
353 chief authors of this draft. SA, MAI, AA and MA contributed to conception, designing, acquisition  
354 of data, manuscript drafting and intellectual input. SA and MoA proposed the hypothesis and study  
355 design and obtained the funding. RA, KH, HR and ABA added the research delivery to the study  
356 centers. MA, MoA, SiA and MFN contributed biochemical, pharmacological and pharmaceutical  
357 inputs along with dosimetry. MKA, SuA, MAz and HZ led the development of data cleaning and  
358 analysis and took responsibility for the results in this draft and future analysis. SA, MoA, RA and  
359 AH drafted the first version of the manuscript. NM, IF, SR, AbH, ZA, AK, ZH, ShaA, HR, ABA,  
360 KH and AAr represented the conduction and validation of the data compilation and analysis in the  
361 manuscript. KN, MSu, SZ, IA, AH, AM, TM, SS, MeA, AA, MA, QAS and MI has overlooked  
362 the conduction and validity of the trial along with contributed to intellectual inputs in study  
363 protocol and methodology along with final manuscript write up. MeA and MI made sure validity  
364 of the data collection, data analysis and ethical considerations in their institutes. All authors are  
365 responsible for their contributions, providing critical edits and final authorization of the article.  
366 The corresponding authors attest the authenticity of that all listed authors meet authorship criteria.



367  
 368 **Figure 1: Study Flow Chart.** Team A: Responsible for the recruitment and SARS-CoV-2 RT-  
 369 PCR testing; Team B: Daily evaluated degree of fever, cough, myalgia, shortness of breath, oxygen  
 370 therapy, how sick do you feel and rate emotional status; Team C: Reported clinical grading scale  
 371 (CGS) on seven-point ordinal scale assessment as 0, 4, 6, 8, 10 and 12 days; Team D conducted  
 372 follow-up PCR and CRP determinations..

<b>Table 1. Baseline characteristics of study participants*</b>				
<b>Parameter</b>	<b>Total (n=313)</b>	<b>Control (n=156)</b>	<b>Honey-Nigella Sativa (n=157)</b>	<b>P-Value<sup>f</sup></b>
<b>Age (Years)</b>				
≤40	156 (49.84)	80 (51.28)	76 (48.4)	0.48
40-59	93 (29.71)	45 (28.85)	48 (30.57)	
60-79	52 (16.61)	26 (16.67)	26 (16.56)	
≥80	12 (3.83)	5 (3.2)	7 (4.45)	
<b>Sex</b>				
Male	178 (56.87)	88 (56.41)	90 (57.32)	0.87
Female	135 (43.13)	68 (43.59)	67 (42.68)	
<b>Profession</b>				
Health care <sup>g</sup>	71 (22.68)	38 (24.36)	33 (21.02)	0.48
Non-Health care	242 (77.32)	118 (75.64)	124 (78.98)	
<b>Co-Morbidities</b>				
Hypertension	99 (31.63)	51 (32.69)	48 (30.57)	0.69
Diabetes Mellitus	115 (36.74)	60 (38.46)	55 (35.03)	0.53
<b>Onset of symptoms before admission</b>				
48 hours	88 (38.1)	49 (41.53)	39 (34.51)	0.22
72 hours	143 (61.9)	69 (58.47)	74 (65.49)	
96 hours	82 (36.44)	38 (35.51)	44 (37.29)	
<b>Severity of Symptoms</b>				
Moderate	210 (67.09)	103 (66.03)	107 (68.15)	0.69
Severe	103 (32.91)	53 (33.97)	50 (31.85)	
<b>ARDS</b>	57 (17.38)	28 (17.95)	29 (16.86)	0.9
<b>Chest X-Ray</b>				
Normal	217 (66.16)	101 (64.74)	116 (73.88)	0.71
Pneumonic Patch	12 (3.66)	8 (5.13)	4 (2.54)	
Unilateral Infiltrates	40 (12.2)	19 (12.18)	21 (13.38)	
Bilateral Infiltrates	59 (17.99)	28 (17.94)	31 (19.74)	
<b>Clinical Grading Score at day 0</b>				
<b>Median Grade Score (IQR)</b>	3 (2-4)	3 (2-4)	3 (2-4)	0.73
2- Not hospitalized with unable to resume normal activities	139 (44.41)	68 (43.59)	71 (45.22)	
3- Hospitalized, not requiring supplemental oxygen	71 (22.68)	35 (22.44)	36 (22.93)	
4- Hospitalized, requiring low flow supplemental oxygen	44 (14.06)	23 (14.74)	21 (13.38)	
5- Hospitalized, requiring high flow supplemental oxygen	59 (18.85)	30 (19.23)	29 (18.47)	
<b>Patients hospitalized in</b>				
Shaikh Zayed Hospital	78 (25.66)	39 (25.83)	39 (25.49)	0.56
Services Institute of Medical Sciences	91 (29.93)	48 (31.79)	43 (28.1)	
Doctors Lounge	52 (17.11)	27 (17.88)	25 (16.34)	

Ali Clinic	83 (27.3)	37 (24.5)	46 (30.07)	
<b>Patients showing symptoms</b>				
Fever	303 (96.81)	152 (97.44)	151 (96.17)	0.53
SOB	106 (33.87)	56 (35.9)	50 (31.85)	0.45
Cough	192 (61.34)	90 (57.69)	102 (64.97)	0.19
Myalgia	169 (53.99)	89 (57.05)	80 (50.96)	0.28
<b>Patients receiving<sup>¥</sup></b>				
Panadol	297 (94.89)	147 (94.23)	150 (97.54)	0.6
Azithromycin	231 (73.8)	120 (76.92)	111 (70.7)	0.21
Montelukast	106 (33.87)	56 (35.9)	50 (31.85)	0.45
Supplemental Oxygen	105 (33.55)	55 (35.25)	50 (31.85)	0.52
Low Molecular Weight Heparin	72 (23)	38 (24.36)	34 (21.66)	0.57
Hydrocortisone	83 (26.52)	45 (28.85)	38 (24.2)	0.35
Multivitamins	147 (46.96)	73 (46.8)	74 (47.13)	0.95
Tanzobactam + Piperacillin	73 (23.32)	42 (26.92)	31 (19.74)	0.13
Ivermectin	114 (36.42)	60 (38.46)	54 (34.39)	0.45
Meropenem	62 (19.81)	35 (22.43)	27 (17.2)	0.25

373 \* Data are presented as no. (%) unless indicated. The Intention-to-Treat analysis was performed on all the  
 374 patients who had undergone randomization. ECMO: Extracorporeal membrane oxygenation; CRP: C-reactive  
 375 protein; AST: Aspartate transaminase; ALT: Alanine transaminase; ECG: Electrocardiography; ARDS: Acute  
 376 respiratory distress syndrome; SOB: Shortness of breath.

377 ‡  $P \leq 0.05$  was determined significant

378 ¶ Medical doctors, nurses and pharmacists.

379 ¥ These medications were part of standard care therapy as per decision of treating physician and  
 380 clinical Management Guidelines for COVID-19 by Ministry of National Health Services, Pakistan.

**Table 2. Primary and Secondary Outcome (Intention-to-Treat Population) \***

PRIMARY OUTCOME	Moderate COVID-19 Cases				Severe COVID-19 Cases			
	Control Group	HNS group	Effect Estimate (95% Confidence Interval) <sup>Ω</sup>	P-Value	Control Group	HNS group	Effect Estimate (95% Confidence Interval) <sup>Ω</sup>	P-Value
<b>Time Taken (days) For alleviation of symptoms in days (IQR) <sup>§</sup></b>	7 (7-8)	4 (3-4)	6.11 (4.23-8.84)	<0.0001	13 (9-15)	6 (5-7)	4.04 (2.46-6.64)	<0.0001
<b>Time Taken (days) for SARS-CoV-2 RT-PCR clearance (IQR) <sup>§</sup></b>	10 (9-12)	6 (6-7)	5.53 (3.76-8.14)	<0.0001	12 (11-17)	8.5 (8-9)	4.32 (2.62-7.13)	<0.0001
<b>Clinical Grading Score at day 6</b>								
Median CGS (IQR)	1 (1-2)	0 (0-1)	0.07 (0.03-0.13)	<0.0001	3 (3-4)	1.5 (0-2)	0.03 (0.01-0.09)	<0.0001
1= Not hospitalized with resumption of normal activities - n (%)	11 (10.68)	68 (63.55)			1 (1.4)	14 (28)		
2= Not hospitalized, but unable to resume normal activities- n (%)	51 (49.51)	35 (32.71)			1 (1.4)	11 (22)		
3= Hospitalized, not requiring supplemental oxygen- n (%)	35 (33.98)	3 (2.8)			10 (13.7)	13 (26)		
4= Hospitalized, requiring low flow supplemental oxygen- n (%)	4 (3.88)	1 (0.93)			23 (31.5)	10 (20)		
5= Hospitalized, requiring high flow nasal oxygen- n (%)	2 (1.94)	0 (0)			13 (17.8)	2 (4)		
6= Hospitalized, requiring mechanical ventilation- n (%)	0 (0)	0 (0)			3 (4.1)	0 (0)		
7=Death- n (%)	0 (0)	0 (0)			2 (2.7)	0 (0)		
<b>SECONDARY OUTCOMES</b>								
<b>Degree of Fever at Day 4<sup>13</sup></b>								
Median Degree Score (IQR)	2 (1-2)	0 (0-1)	0.05 (0.03-0.1)	<0.0001	2 (1-3)	2 (1-2)	0.21 (0.09-0.46)	0.0001
0= No Fever- n (%)	4 (3.88)	63 (58.88)			2 (3.77)	11 (22)		
1= Mild Fever- n (%)	30 (29.13)	31 (28.97)			12 (22.64)	13 (26)		
2= Moderate Fever- n (%)	60 (58.25)	12 (11.21)			23 (43.4)	24 (48)		
3= Severe Fever- n (%)	9 (8.74)	1 (0.93)			16 (30.19)	2 (4)		

<b>Mean CRP Level at Day 6 (mg/l) ± SD</b>	9.44 ± 4.94 (n=67)	6.15 ± 2.45 (n=61)	-3.16 (-4.52 - - 1.81)	<0.0001	23.32 ± 8.73 (n=44)	15.83 ± 7.17 (n=36)	-8.48 (-11.82 - - 5.13)	<0.0001
<b>Severity of Symptoms at Day 8<sup>†‡</sup></b>								
Median Score (IQR)	0 (0-2)	0 (0-0)	0.009 (0.001- 0.08)	<0.0001	2(1-3)	0(0-1)	0.1 (0.04-0.24)	<0.0001
0= Asymptomatic- n (%)	58 (56.31)	105 (98.13)			10 (19.61)	35 (70)		
1= Mild Symptoms- n (%)	18 (17.48)	2 (1.87)			15 (29.41)	7 (14)		
2= Moderate Symptoms- n (%)	21 (20.39)	0 (0)			4 (7.84)	2 (4)		
3= Severe Symptoms- n (%)	6 (5.83)	0 (0)			22 (43.14)	6 (12)		
<b>Clinical Grading Score at day 10<sup>†‡</sup></b>								
Median Score (IQR)	1 (1-2)	1 (1-2)	0.07 (0.02-0.21)	<0.0001	4 (2-4)	1 (1-1)	0.05 (0.02-0.15)	<0.0001
1= Not hospitalized with resumption of normal activities- n (%)	71 (68.93)	103 (96.26)			10 (18.87)	39 (78)		
2= Not hospitalized, but unable to resume normal activities- n (%)	26 (25.24)	3 (2.8)			13 (24.53)	2 (4)		
3= Hospitalized, not requiring supplemental oxygen- n (%)	2 (1.94)	0			2 (3.77)	3 (6)		
4= Hospitalized, requiring low flow supplemental oxygen- n (%)	2 (1.94)	1 (0.93)			16 (30.19)	4 (8)		
5= Hospitalized, requiring high flow nasal oxygen- n (%)	1 (0.97)	0			4 (7.55)	1 (2)		
6= Hospitalized, requiring mechanical ventilation- n (%)	1 (0.97)	0			4 (7.55)	1 (2)		
7=Death- n (%)	0 (0)	0			4 (7.55)	0 (0)		
<b>30 Day Mortality<sup>€</sup></b>	1 (1.37)	0	0 (0-0)	0.49	10 (18.87)	2 (4)	0.18 (0.02-0.92)	0.029
<b>ADDITIONAL OUTCOMES</b>								
<b>Median time to clinical improvement of severity of symptoms (95% CI) <sup>¶</sup> — days</b>								
Improvement of one category on ordinal scale	5 (5-6)	3 (3-4)	2.88 (2.10-3.94)	<0.0001	5 (5-7)	3 (3-4)	2.26 (1.48-3.45)	<0.0001
Improvement of two category on ordinal scale	8 (7-9)	5 (4-5)	4.18 (2.97-5.89)	<0.0001	12 (7-non-estimable)	5 (5-6)	2.59 (1.6-4.14)	<0.0001
Achievement of normal status on ordinal scale	8 (8-9)	5 (4-6)	4.49 (3.15-6.38)	<0.0001	13 (10-non-estimable)	7 (6-8)	2.74 (1.68-4.49)	<0.0001

<b>Median time to clinical improvement of degree of fever (95% CI) <sup>l</sup> — days</b>								
Improvement of one category on ordinal scale	5 (4-5)	3 (non-estimable)	2.54 (1.87-3.46)	<0.0001	3 (3-4)	3 (2-3)	1.80 (1.18-2.75)	0.0003
Improvement of two category on ordinal scale	7.5 (7-8)	4 (4-5)	3.96 (2.84-5.52)	<0.0001	7 (6-8)	5 (4-5)	2.23 (1.45-3.43)	<0.0001
Achievement of normal status on ordinal scale	8 (7-8)	4 (4-5)	4.17 (2.98-5.84)	<0.0001	10 (8-11)	6 (6-7)	2.64 (1.7-4.11)	<0.0001
<b>Median time to clinical improvement of cough (95% CI) <sup>h</sup> — days</b>								
Improvement of one category on ordinal scale	4 (4-6)	3 (non-estimable)	2.32 (1.53-3.53)	<0.0001	4 (3-4)	3 (3-4)	1.04 (0.66-1.63)	0.82
Improvement of two category on ordinal scale	6 (5-6)	5 (4-5)	2.27 (1.46-3.55)	<0.0001	7 (6-8)	5 (5-6)	1.59 (0.98-2.59)	0.03
Achievement of normal status on ordinal scale	7 (6-8)	5 (4-6)	2.67 (1.73-4.12)	<0.0001	9 (8-10)	6 (6-7)	2.04 (1.26-3.31)	0.001
<b>Median time to clinical improvement of shortness of breath (95% CI) <sup>g</sup> — days</b>								
Improvement of one category on ordinal scale	2 (2-non-estimable)	2 (non-estimable)	1.33 (0.14-12.82)	0.617	6 (4-11)	3 (3-4)	2.65 (1.7-4.14)	<0.0001
Improvement of two category on ordinal scale	2 (non-estimable)	2 (non-estimable)	1 (0.09-11.03)	1	7 (6-12)	4 (4-5)	2.94 (1.84-4.7)	<0.0001
Achievement of normal status on ordinal scale	2 (2-non-estimable)	2 (non-estimable)	1.33 (0.14-12.82)	0.617	13 (8-non-estimable)	6 (4-6)	2.39 (1.48-3.87)	<0.0001
<b>Median time to clinical improvement of myalgia (95% CI) <sup>h</sup> — days</b>								
Improvement of one category on ordinal scale	4 (3-4)	3 (non-estimable)	2.3 (1.52-3.46)	<0.0001	4 (3-7)	3 (3-4)	1.83 (1.1-3.05)	0.0033
Improvement of two category on ordinal scale	6 (6-7)	4 (4-5)	3.09 (1.92-4.98)	<0.0001	8.5 (6-11)	5 (4-5)	2.64 (1.53-4.54)	<0.0001
Achievement of normal status on ordinal scale	6 (6-7)	4 (4-5)	3.34 (2.14-5.23)	<0.0001	9 (7-11)	5 (4-6)	2.75 (1.62-4.69)	<0.0001
<b>Median time to clinical improvement of “how sick do you feel” (95% CI) <sup>z</sup> — days</b>								
Improvement of one category on ordinal scale	5 (4-5)	3 (non-estimable)	2.58 (1.9-3.51)	<0.0001	5 (4-9)	4 (3-4)	1.82 (1.12-2.77)	0.0012
Improvement of two category on ordinal scale	7 (7-8)	5 (4-5)	3.27 (2.37-4.51)	<0.0001	8 (7-non-estimable)	5 (5-6)	2.18 (1.37-3.48)	0.0002
Achievement of normal status on ordinal scale	8 (7-9)	5 (4-6)	3.55 (2.55-4.93)	<0.0001	13 (10-non-estimable)	7 (6-8)	2.87 (1.75-4.69)	<0.0001

381 \* The Intention-to-Treat analysis was performed on all the patients who had undergone randomization. n=number of patients, IQR: Interquartile Range, ECMO:  
382 Extracorporeal membrane oxygenation; CRP: C-reactive protein.

383 **Ω** The effect estimate for time to symptom alleviation, viral clearance and median time to clinical improvements are hazard ratios, for CRP are mean differences,  
384 and for ordinal variables are odds ratios.

385 **¥** Median number of days (95% confidence interval) with hazard ratio estimation using log-rank test.

386 **Ʒ** Ordinal logistic regression models assuming proportional odds applied (multivariable regression models to adjust for the effects of patient age, gender, baseline  
387 clinical status grade, and history of diabetes/hypertension.)

388 **‡** Time taken for the alleviation of symptoms was the difference between date of enrollment and becoming clinically asymptomatic.

389 **§** Viral load clearance was the difference between date of first positive and next negative SARS-CoV-2 RT-PCR.

390 **†** Clinical status grading was assessed on 6<sup>th</sup> and 10<sup>th</sup> day using the seven-level ordinal scale representing effect estimate as odds ratio (95% confidence interval).

391 **‡** Fever is classified as mild, moderate and severe. None (0) 98-99 °F, mild (1) <100 °F, moderate (2) 100-101.9 °F, severe (3) ≤ 102°F

392 **β** Mean CRP ± Standard deviation for number of patients (n) shown with effect estimate as mean difference adjusted for the co-variants

393 **¶** Severity of symptoms is classified as mild, moderate and severe. Mild denotes symptoms of upper respiratory tract viral infection i.e. low grade fever, dry  
394 cough, sore throat, nasal congestion, malaise, Moderate are respiratory symptoms (fever, cough and shortness of breath) without signs of severe pneumonia and  
395 severe is classified as fever associated with severe dyspnoea, respiratory distress, tachypnea (> 30 breaths/min), and hypoxia (SpO2 < 90% on room air)


396 **€** Fischer exact P value (2-tail), significant if <0.05.

397 **h** Cough is categorized from 0 to 3; None (0), Mild (1) occasional, transient cough, Moderate (2) frequent cough, slightly influencing day time activities, Severe  
398 (3): frequent cough, significantly influencing daytime activities


399 **q** Shortness of Breath is grouped as Grade 1, Grade 2, Grade 3, Grade 4 and Grade 5. Grade 1=Not troubled by breathlessness except on strenuous exercise,  
400 Grade 2=Short of breath when hurrying on the level or walking up a slight hill, Grade 3=Walks slower than most people on the level, stops after a mile or so, or  
401 stop after 15 minutes walking at own pace, Grade 4=Stops for breath after walking about 100 yds or a few minutes on level ground and Grade 5=Too breathless  
402 to breathless when undressing.

403 **b** Myalgia is graded as none (0), mild (1), moderate (2), and severe (3) on subjective basis.

404 **Σ** How Sick Do You Feel is categorized as none (0), mild (1), moderate (2), and severe (3) on subjective basis.



405  
 406 **Figure 2. Kinetic changes in outcomes.** A. Mean oxygen saturation spO<sub>2</sub> over time in severe  
 407 cases; Kaplan-Meier probability curves for time taken (in days) for alleviation of symptoms in  
 408 moderate (B) and severe cases (C); Kaplan-Meier probability curves for time taken (in days) for  
 409 viial clearance in moderate (D) and severe cases (E). ns = non-significant, \* = P<0.05, \*\* = P<0.001,  
 410 \*\*\* = P<0.0001



411

412 **Figure 3. Kinetics of clinical status grading in Ordinal-Scale in COVID-19 patients.** The  
413 Figure shows kinetic changes in clinical grade score (in 7-point ordinal-scale) in COVID-19  
414 patient receiving the treatment (HNS) or placebo (Control). Note increases numbers of patients  
415 within scale 1 in the HNS group both for the moderate and severe cases.

## REFERENCES:

1. Wang L-s, Wang Y-r, Ye D-w, Liu Q-q. A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence. *International Journal of Antimicrobial Agents*. 2020:105948.
2. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. 2020.
3. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. 2020;382(19):1787-99.
4. Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. 2020.
5. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of Covid-19 — Final Report. 2020.
6. Spinner CD, Gottlieb RL, Criner GJ, López JRA, Cattelan AM, Viladomiu AS, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. 2020;324(11):1048-57.
7. Kewan T, Covut F, Al-Jaghbeer MJ, Rose L, Gopalakrishna KV, Akbik B. Tocilizumab for treatment of patients with severe COVID-19: A retrospective cohort study. *EClinicalMedicine*. 2020;24:100418.
8. Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report. 2020.
9. Kwakman PH, Zaat SA. Antibacterial components of honey. *IUBMB life*. 2012;64(1):48-55.
10. Abd-El Aal A, El-Hadidy M, El-Mashad N, El-Sebaie A. Antimicrobial effect of bee honey in comparison to antibiotics on organisms isolated from infected burns. *Annals of Burns and fire disasters*. 2007;20(2):83.
11. Khan SU, Anjum SI, Rahman K, Ansari MJ, Khan WU, Kamal S, et al. Honey: Single food stuff comprises many drugs. *Saudi journal of biological sciences*. 2018;25(2):320-5.
12. Forouzanfar F, Bazzaz BSF, Hosseinzadeh H. Black cumin (*Nigella sativa*) and its constituent (thymoquinone): a review on antimicrobial effects. *Iranian journal of basic medical sciences*. 2014;17(12):929.
13. Majdalawieh AF, Fayyad MW. Immunomodulatory and anti-inflammatory action of *Nigella sativa* and thymoquinone: A comprehensive review. *International immunopharmacology*. 2015;28(1):295-304.
14. Hashemipour MA, Tavakolineghad Z, Arabzadeh S, Iranmanesh Z, Nassab SJWacocr, practice. Antiviral Activities of Honey, Royal Jelly, and Acyclovir Against HSV-1. 2014;26(2):47.
15. Shahzad A, Cohrs RJTb. In vitro antiviral activity of honey against varicella zoster virus (VZV): A translational medicine study for potential remedy for shingles. 2012;3(2).
16. Hashem H. IN Silico approach of some selected honey constituents as SARS-CoV-2 main protease (COVID-19) inhibitors. 2020.
17. Almasaudi SB, Al-Nahari AA, El Sayed M, Barbour E, Al Muhayawi SM, Al-Jaouni S, et al. Antimicrobial effect of different types of honey on *Staphylococcus aureus*. *Saudi journal of biological sciences*. 2017;24(6):1255-61.
18. Jenkins R, Cooper R. Improving antibiotic activity against wound pathogens with manuka honey in vitro. *PLoS One*. 2012;7(9).
19. Boukraâ L. Honey in traditional and modern medicine. Boca Raton, FL: CRC Press; 2016.
20. Abuelgasim H, Albury C, Lee J. Effectiveness of honey for symptomatic relief in upper respiratory tract infections: a systematic review and meta-analysis. *BMJ Evidence-Based Medicine*. 2020:bmjebm-2020-111336.
21. Oyero OG, Toyama M, Mitsuhiro N, Onifade AA, Hidaka A, Okamoto M, et al. Selective inhibition of hepatitis c virus replication by Alpha-zam, a *Nigella sativa* seed formulation. *African journal of traditional, complementary and alternative medicines*. 2016;13(6):144-8.
22. Barakat EMF, El Wakeel LM, Hagag RS. Effects of *Nigella sativa* on outcome of hepatitis C in Egypt. *World journal of gastroenterology: WJG*. 2013;19(16):2529.
23. Salem ML, Hossain MS. Protective effect of black seed oil from *Nigella sativa* against murine cytomegalovirus infection. *International journal of immunopharmacology*. 2000;22(9):729-40.
24. Ulasli M, Gurses SA, Bayraktar R, Yumrutas O, Oztuzcu S, Igci M, et al. The effects of *Nigella sativa* (Ns), *Anthemis hyalina* (Ah) and *Citrus sinensis* (Cs) extracts on the replication of coronavirus and the expression of TRP genes family. *Molecular biology reports*. 2014;41(3):1703-11.
25. Koshak AE, Koshak EA. *Nigella sativa* l. as a potential phytotherapy for covid-19: A mini-review of in-silico studies. *Current Therapeutic Research*. 2020:100602.

26. Kulyar MF-e-A, Li R, Mehmood K, Waqas M, Li K, Li JJP. Potential influence of *Nigella sativa* (Black cumin) in reinforcing immune system: A hope to decelerate the COVID-19 pandemic. 2020:153277.
27. Eteraf-Oskouei T, Najafi MJ. Traditional and modern uses of natural honey in human diseases: a review. 2013;16(6):731.
28. Ameen NMA, Altubaigy F, Jahangir T, Mahday IA, Mohammed EA, Musa OAAJJoMPR. Effect of *Nigella sativa* and bee honey on pulmonary, hepatic and renal function in Sudanese in Khartoum state. 2011;5(31):6857-63.
29. Bhatti I, Inayat S, Uzair B, Menaa F, Bakhsh S, Khan H, et al. Effects of *nigella sativa* (Kalonji) and honey on lipid profile of hyper lipidemic smokers. 2016;50(3):376-84.
30. Moghimipour E, Ghorbani A, Malayeri A, Siahpoosh A, Khodadoost M, Rajaeipour M, et al. Evaluation of *Nigella sativa* and honey combination for treatment of kidney stone: a randomized, placebo controlled clinical trial. 2019;5(1).
31. Javadi SMR, Hashemi M, Mohammadi Y, MamMohammadi A, Sharifi A, Makarchian HRJAcB. Synergistic effect of honey and *Nigella sativa* on wound healing in rats. 2018;33(6):518-23.
32. Al Jaouni SK, Halawa T, Hussein A, Al Najjar S, Almuhayawi MS, Harakeh SJJAH. *Nigella sativa* and Saudi honey diminish infections and improve the survival in a kostmann's syndrome patient: Case report. 2017;8(3):119.
33. Clinical Management Guidelines for COVID-19. Ministry of National Health Services, Pakistan. Third Version.
34. Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA. 2020;324(5):460-70.
35. Pan H, Peto R, Abdool Karim Q, Alejandria M, Heno Restrepo AM, Hernandez Garcia C, et al. Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results. 2020:2020.10.15.20209817.
36. Tavakkoli A, Mahdian V, Razavi BM, Hosseinzadeh H. Review on Clinical Trials of Black Seed (*Nigella sativa*) and Its Active Constituent, Thymoquinone. Journal of pharmacopuncture. 2017;20(3):179-93.
37. Cianciosi D, Forbes-Hernández TY, Afrin S, Gasparrini M, Reboredo-Rodríguez P, Manna PP, et al. Phenolic compounds in honey and their associated health benefits: A review. 2018;23(9):2322.
38. Ahmed A, Khan RA, Azim MK, Saeed SA, Mesaik MA, Ahmed S, et al. Effect of natural honey on human platelets and blood coagulation proteins. Pakistan journal of pharmaceutical sciences. 2011;24(3):389-97.
39. Al-Ghamdi MJJoe. The anti-inflammatory, analgesic and antipyretic activity of *Nigella sativa*. 2001;76(1):45-8.
40. Alzubier AA, Okechukwu PNJWASET. Investigation of anti-inflammatory, antipyretic and analgesic effect of Yemeni Sidr Honey. 2011;5:41-6.